OKYO Pharma Ltd

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It targets to cure and prevent the following conditions: dry eye disease, non-infectious anterior uveitis, allergic conjunctivitis, and ocular pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma said it will work with US group AmbioPharm on the investigational new drug (IND) filing of dry eye disease (DED) treatment OK-101. A US filing is expected in the final quarter of 2022, OKYO reiterated today with a first human trial early scheduled for early in 2023 OKYO added this will be a phase 2 trial, skipping the normal phase 1 study, as the drug is administered topically.

OKYO Pharma to work with AmbioPharm on dry eye IND filing

LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2022.

News for OKYO Pharma Ltd Stock (OKYO)